Commentary: Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis

Key Points

• Tebentafusp shows promising efficacy in treating metastatic uveal melanoma, indicating a potential improvement in patient outcomes.
• The systematic review synthesizes findings from multiple studies; meta-analysis results support a significant benefit over conventional therapies.
• Assessment includes safety evaluations, finding that tebentafusp is well-tolerated with manageable adverse effects.
• This analysis highlights the need for continued research to optimize treatment strategies for metastatic uveal melanoma.